The number of patients with any adverse events (AEs), patients with drug-related AEs.

Patients from the Treated Set (TS).

Patients who discontinued treatment due to adverse events including deaths.

Patients from the Treated Set (TS).

Mentation, behaviour and mood is scored from 0-16 in UPDRS I (0 = best score to 16 = worst score), result of motor examination scored from 0-108 in UPDRS III (0=no disability, 108=maximum disability) . The change was calculated by Baseline value minus value at visit 3. A decrease (change>0) in the score means improvement.

Patients from the Full Analysis Set (FAS) which includes all treated patients who have data for at least one post baseline visit.

The CGI-I was rated (from 1: very much improved, to 7: very much worse) to assess the overall status of Parkinson's disease. The clinician rated how much a patient's condition had improved or worsened relative to baseline state. The patients are considered to be a CGI-I responder if they are rated at least by minimally improved.

Patients from FAS

The visual analogue scale measures overall patient satisfaction with treatment on a continuous axis ranging from 0 (no satisfaction) to 100 (highest patient satisfaction). The change was calculated by the value at the final visit minus the value at baseline. Therefore, an increase (change>0) reflects an improvement in patient satisfaction.

Patients from FAS with evaluable data in VAS at baseline and at visit 3.

The Morisky Medication Adherence Scale with 4 items was administered to examine medication adherence. The score ranges from 0 (best adherence) to 4 (worst adherence). The change was calculated by the value at baseline minus the value at visit 3. Therefore, a change >0 reflects an improvement

Patients from FAS with evaluable data in the Morisky scale for baseline and at visit 3.